Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Stem Cells to Aid Search for New Drugs in Hard-to-Treat Conditions

Published: Monday, December 10, 2012
Last Updated: Monday, December 10, 2012
Bookmark and Share
StemBANCC consortium aims to derive 1,500 stem cell lines from 500 patients across eight diseases.

Stem cells are to be used in a £45m effort to look at providing new treatments for a host of complex conditions affecting large numbers of people, including Alzheimer's, Parkinson's, autism and diabetes.

However, it’s not the stem cells themselves that would form the new treatments. Instead, the stem cells would provide a platform to transform the process of discovering new drugs.

A Europe-wide consortium of over 20 universities and 10 pharmaceutical companies, led by Oxford University and Roche, is to generate a giant resource of stem cells derived from patients' skin or blood cells.

The StemBANCC consortium aims to derive 1,500 stem cell lines from 500 patients across eight diseases, using the techniques developed by Japanese scientist Shinya Yamanaka that saw him win a share of this year’s Nobel Prize for Physiology or Medicine.

'This has been shown for two or three patients for several indications; the proof of concept is there,' says Martin Graf, StemBANCC coordinator and head of Roche's Stem Cell Platform in Basel, Switzerland, explaining the scale of the project. 'We now plan to create 1,500 iPS cell lines from 500 patients.'

The researchers will then be able to use the 'induced pluripotent' stem cells, or iPS cells, to generate different tissue types - nerve cells, heart muscle, blood vessels, liver or pancreas cells, etc - against which drug compounds can be screened.

Testing drug candidates from the start in cells derived from patients - and so are directly relevant to the disease - will be much more relevant for coming up with effective treatments, the researchers say.

This approach to drug discovery could be particularly important in the diseases the researchers are interested in, where it has proved so difficult to come up with new treatments and where the pharmaceutical industry's most promising new drug candidates have often failed in late-stage trials.

'It’s the perfect platform for finding drugs. It's superior because we are looking directly at human cells from the patient, capturing the genetic complexity of the disease,' says Dr Zameel Cader, a consultant neurologist at the University of Oxford and principal scientist of StemBANCC.

Currently, many drugs fail late on in development because the tests used in the initial stages simply do not reflect what happens when the drug is administered in patients.

It is largely standard to screen compounds in lab cell lines that are often amenable to study but are nothing like cells in patients. Promising compounds then go into studies in animals before small-scale safety trials in humans look at safety.

It is only in larger trials, and after many millions of pounds have been spent, that it becomes apparent that the drugs have little or no effect in patients.

'The drug discovery process is flawed and isn't working. It needs reshaping, and stem cells may help provide this,' says Dr Cader.

StemBANCC would provide a good supply of cells directly from patients that 'recapitulate' the disease in the lab, and against which compounds can be tested from the start, the researchers say.

Heart, kidney and liver cells would also allow toxicological screens to help spot potential side effects early.

Dr Cader explains: 'The generation of the [stem cell] bank is the easy part, relatively speaking. The harder part is to show we can identify abnormalities [in the cell lines] relevant to disease.

'We believe we will be able to see abnormalities that are there in the disease. It will be hard. But if we find them, it will be superb. We can then apply [drug] compounds into our assays [lab-based tests] and see if these compounds correct the cellular abnormalities.'

The consortium will generate iPS cells from groups of patients with the following conditions: Alzheimer's, Parkinson's, autism, schizophrenia, bipolar disorder, migraine, chronic pain and diabetes.

The intention is to make the cell lines generally available to researchers help to improve the discovery of new drugs for these hard-to-treat conditions.

'Because the stem cells can be expanded indefinitely, we can essentially produce an infinite number of these patient-derived cells to work with,' explains Dr Sally Cowley of Oxford University. 'They can be stored, shipped around the world, and potentially made accessible to any researcher anywhere.'

Dr Cowley, who runs the stem cell facility at the Oxford Stem Cell Institute, part of the Oxford Martin School, adds: 'People may be working with these cell lines for decades, if we do it right.'

The €55.6 million funding over five years is made up of €26 million from the European Union's Innovative Medicines Initiative and €21 million in 'in kind' contributions from the participating drug firms in the European pharmaceutical industry association EFPIA. Contributions from other sources make up the rest.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Funding Boost for Diabetes Research
Programme of research could be a game-changer for people with Type 1 diabetes and insulin-dependent Type 2 diabetes.
Friday, July 24, 2015
Ebola Vaccine Trial Begins in Senegal
A clinical trial to evaluate an Ebola vaccine has begun in Dakar, Senegal, after initial research started at the Jenner Institute, Oxford University.
Thursday, July 16, 2015
New Insight into Recombination and Sex Chromosomes
Not only does the platypus have some odd physical features, an updated version of its genome has also underscored the unusual genetic characteristics that it harbors.
Tuesday, May 12, 2015
Protein Clue To Sudden Cardiac Death
A protein has been shown to have a surprising role in regulating the 'glue' that holds heart cells together, a finding that may explain how a gene defect could cause sudden cardiac death.
Tuesday, February 17, 2015
Oxford Vaccine Group Begins First Trial of New Ebola Vaccine
Oxford University doctors and scientists are starting the first safety trial of an experimental preventative Ebola vaccine regimen being developed by the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen).
Wednesday, January 07, 2015
New Vaccine Generates Strong Immune Response Against Hepatitis C
A new hepatitis C vaccine has shown promising results in an early clinical trial at Oxford University, generating strong and broad immune responses against the virus causing the disease.
Friday, November 07, 2014
Investment In Cancer Research At Oxford University
Centre for Molecular Medicine to focus on cancer genomics and molecular diagnostics, through a partnership with the Chan Soon-Shiong Institute.
Friday, October 24, 2014
A-maize-ing Double Life of a Genome
Study findings could help current efforts to improve existing crop varieties.
Tuesday, July 15, 2014
Genetic Tracking Identifies Cancer Stem Cells in Patients
The gene mutations driving cancer have been tracked for the first time in patients back to a distinct set of cells at the root of cancer – cancer stem cells.
Friday, May 16, 2014
Eating Organic Food Doesn't Lower Overall Cancer Risk
Women who always or mostly eat organic foods have the same likelihood of developing cancer as women who eat conventionally produced foods.
Tuesday, April 01, 2014
New Trial of Personalized Cancer Treatment Begins in Oxford
Phase I trial in Oxford will investigate a new drug, called CXD101.
Tuesday, March 18, 2014
Interactive Map of Human Genetic History Revealed
Study identifies, dates and characterizes genetic mixing between populations.
Tuesday, February 18, 2014
UK Scientists to Begin Trial of Potential HIV Cure
Scientists and clinicians from five leading UK universities will begin a groundbreaking clinical trial next year to test a possible cure for HIV infection.
Tuesday, November 26, 2013
Nanoparticles to Probe Mystery Sperm Defects Behind Infertility
A way of using nanoparticles to investigate the mechanisms underlying 'mystery' cases of infertility has been developed.
Monday, November 18, 2013
Scientists Break Blood-Brain Barrier to Allow Cancer Drugs In
Oxford University scientists have found a way of delivering drugs more effectively to treat life-threatening cancers that have spread to the brain.
Tuesday, October 15, 2013
Scientific News
NIH Study Finds Calorie Restriction Lowers Some Risk Factors for Age-Related Diseases
Two-year trial did not produce expected metabolic changes, but influenced other life span markers.
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
Low-level Arsenic Exposure Before Birth Associated with Early Puberty in Female Mice
Study examine whether low-dose arsenic exposure could have similar health outcomes in humans.
Inciting an Immune Attack On Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
‘Mutation-Tracking’ Blood Test for Breast Cancer
Scientists have developed a blood test for breast cancer able to identify which patients will suffer a relapse after treatment, months before tumours are visible on hospital scans.
Cellular Contamination Pathway for Heavy Elements Identified
Berkeley Lab scientists find that an iron-binding protein can transport actinides into cells.
Intensity of Desert Storms May Affect Ocean Phytoplankton
MIT study finds phytoplankton are extremely sensitive to changing levels of desert dust.
Common ‘Heart Attack’ Blood Test May Predict Future Hypertension
Small rises in troponin levels may have value as markers for subclinical heart damage and high blood pressure.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!